Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | 最新消息 - 中國醫藥大學附設醫院

:::

院外單位健康通報

實名登記系統

"> 回首頁LOGO按鈕

繁簡 EN

最新消息

News & Message

:::

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

最新消息

2026/2/3

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer

回上頁

相關文章

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

$INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer$

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

側邊開關圖示

中國醫點通

百度搜狗 360搜索阎王下山幸运一击生化危机鹊刀门传奇敢问路在何方

<code id='30555'></code><style id='b28c8'></style>

<acronym id='aa2bf'></acronym>

<center id='65c78'><center id='46f84'><tfoot id='47ad8'></tfoot></center><abbr id='7b371'><dir id='78e38'><tfoot id='a5032'></tfoot><noframes id='901bb'>

<optgroup id='ab6bd'><strike id='0f717'><sup id='2581c'></sup></strike><code id='7f0f7'></code></optgroup>

<b id='494ae'><label id='e3f56'><select id='39988'><dt id='27c69'><span id='36532'></span></dt></select></label></b><u id='d2823'></u>

~~<i id='cf9ef'><strike id='c820c'><tt id='43f5b'><pre id='789af'></pre></tt></strike></i>~~